MVP: Sullivan & Cromwell's Matt Hurd
Matt Hurd of Sullivan & Cromwell LLP recently led Pfizer's acquisition of Seagen, a global biotech company specializing in cancer medicines, in a $43 billion all-cash deal, earning him a spot...To view the full article, register now.
Already a subscriber? Click here to view full article